Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Deremer

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 17, 2015
Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patientsMegan E Hartranft, Amber B Clemmons, David L DeRemer, et al.
American Journal of Hematology|September 4, 2008
Decitabine as "bridge therapy" to a MUD transplant in relapsed AML postautologous stem cell transplantationCelalettin Ustun, Abhishek Kalla, Stephanie Farrow, et al.
Journal of Pharmacy Practice|July 20, 2016
Clinical and Cost Comparison Evaluation of Inpatient Versus Outpatient Administration of EPOCH-Containing Regimens in Non-Hodgkin LymphomaSarah S Evans, Arpita S Gandhi, Amber B Clemmons, et al.
Pharmacotherapy|December 5, 2012
Antiangiogenic therapy for cancer: an updateBelal Al-Husein, Maha Abdalla, Morgan Trepte, et al.
Pharmacogenomics|June 6, 2026
Considerations for the clinical implementation of DPYD and UGT1A1-guided chemotherapyMary-Pearl Ojukwu, Carlos Vegas, Emily J Cicali, et al.
Pharmacotherapy|February 19, 2016
Emerging Role of Olanzapine for Prevention and Treatment of Chemotherapy-Induced Nausea and VomitingDavid L DeRemer, Amber B Clemmons, Julianne Orr, et al.
Cancer Chemotherapy and Pharmacology|November 21, 2025
Severe toxicity following genotype-guided reduced 5-FU dose in a heterozygous DPYD c.2846A>T carrier with stage III anal carcinoma: A case reportMadeline L Norris, David L DeRemer, Julio D Duarte, et al.
Clinical Science (London, England : 1979)|April 14, 2011
Angiotensin receptor blockers and angiogenesis: clinical and experimental evidenceLauren M Willis, Azza B El-Remessy, Payaningal R Somanath, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|May 10, 2015
Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplantStephen Michael Clark, Amber B Clemmons, Lindsay Schaack, et al.
Cancer Treatment Reviews|March 18, 2022
Emergence of ocular toxicities associated with novel anticancer therapeutics: What the oncologist needs to knowAzka Ali, Ankit A Shah, Lauren J Jeang, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 17, 2015
Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patientsMegan E Hartranft, Amber B Clemmons, David L DeRemer, et al.
American Journal of Hematology|September 4, 2008
Decitabine as "bridge therapy" to a MUD transplant in relapsed AML postautologous stem cell transplantationCelalettin Ustun, Abhishek Kalla, Stephanie Farrow, et al.
Journal of Pharmacy Practice|July 20, 2016
Clinical and Cost Comparison Evaluation of Inpatient Versus Outpatient Administration of EPOCH-Containing Regimens in Non-Hodgkin LymphomaSarah S Evans, Arpita S Gandhi, Amber B Clemmons, et al.
Pharmacotherapy|December 5, 2012
Antiangiogenic therapy for cancer: an updateBelal Al-Husein, Maha Abdalla, Morgan Trepte, et al.
Pharmacogenomics|June 6, 2026
Considerations for the clinical implementation of DPYD and UGT1A1-guided chemotherapyMary-Pearl Ojukwu, Carlos Vegas, Emily J Cicali, et al.
Pharmacotherapy|February 19, 2016
Emerging Role of Olanzapine for Prevention and Treatment of Chemotherapy-Induced Nausea and VomitingDavid L DeRemer, Amber B Clemmons, Julianne Orr, et al.
Cancer Chemotherapy and Pharmacology|November 21, 2025
Severe toxicity following genotype-guided reduced 5-FU dose in a heterozygous DPYD c.2846A>T carrier with stage III anal carcinoma: A case reportMadeline L Norris, David L DeRemer, Julio D Duarte, et al.
Clinical Science (London, England : 1979)|April 14, 2011
Angiotensin receptor blockers and angiogenesis: clinical and experimental evidenceLauren M Willis, Azza B El-Remessy, Payaningal R Somanath, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|May 10, 2015
Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplantStephen Michael Clark, Amber B Clemmons, Lindsay Schaack, et al.
Cancer Treatment Reviews|March 18, 2022
Emergence of ocular toxicities associated with novel anticancer therapeutics: What the oncologist needs to knowAzka Ali, Ankit A Shah, Lauren J Jeang, et al.
Pageof 5